The KINECT-PRO™ study, recently published in CNS Spectrums (@CambridgeCore), contributes to the growing body of research focused on understanding how treatment for tardive dyskinesia can improve patients’ quality of life and daily functioning.

Neurocrine Vice President of Medical Affairs Nina Thomas shares her thoughts on the importance of incorporating patient-reported outcome measures into research.

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-publication-kinect-protm